Linda Kozick Net Worth

Linda Kozick biography

Linda Kozick serves as Independent Director of the Company. From January 2011 to July 2015, Ms. Kozick served as Head of Immuno-Oncology, Oncology Product and Portfolio Strategy for Opdivo and Yervoy Life Cycle Management at Bristol-Myers Squibb Co. Ms. Kozick obtained an M.B.A. from Chapman University. Ms. Kozick also received an M.S. in Molecular Immunology and a B.S. in Medical Technology from SUNY Upstate Medical University.

What is the salary of Linda Kozick?

As the Independent Director of RAPT Therapeutics, the total compensation of Linda Kozick at RAPT Therapeutics is $200,640. There are 9 executives at RAPT Therapeutics getting paid more, with Rodney Young having the highest compensation of $2,296,220.

How old is Linda Kozick?

Linda Kozick is 62, she's been the Independent Director of RAPT Therapeutics since 2016. There are 1 older and 11 younger executives at RAPT Therapeutics. The oldest executive at RAPT Therapeutics, Inc. is Mary Gray, 67, who is the Independent Director.

What's Linda Kozick's mailing address?

Linda's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at RAPT Therapeutics

Over the last 5 years, insiders at RAPT Therapeutics have traded over $79,325,123 worth of RAPT Therapeutics stock and bought 4,298,405 units worth $48,553,258 . The most active insiders traders include Peter Svennilson, David V Goeddel és Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $127,774. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth $20,456.

What does RAPT Therapeutics do?

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

RAPT Therapeutics executives and stock owners

RAPT Therapeutics executives and other stock owners filed with the SEC include:

• Rodney Young,
  Chief Financial Officer
• Brian Wong,
  President, Chief Executive Officer, Director
• Dirk Brockstedt,
  Chief Scientific Officer
• Dr. Brian Russell Wong M.D., Ph.D.,
  CEO, Pres & Director
• Dr. William Ho,
  Chief Medical Officer
• Dr. Dirk G. Brockstedt Ph.D.,
  Chief Scientific Officer
• Mary Gray,
  Independent Director
• Wendye Robbins,
  Independent Director
• William Rieflin,
  Independent Director
• Linda Kozick,
  Independent Director
• Michael Giordano,
  Independent Director
• Peter Svennilson,
  Director
• William Ho,
  Chief Medical Officer
• Lisa Moore,
  Vice President - Business Development and Strategy
• Phyllis Gray,
  Vice President of Human Resources
• Paul Kassner,
  Senior Vice President - Quantitative and Computational Biology
• Dr. David Wustrow,
  Sr. VP of Drug Discovery & Preclinical Devel.
• Dr. Paul Kassner,
  Sr. VP of Quantitative & Computational Biology
• Steve Young Ph.D.,
  VP of Technology
• Rodney K. B. Young,
  CFO, Principal Accounting Officer & Sec.
• Group Ii, Lp Column Group I...,
  
• Group Ii, Lp Column Group I...,
  
• Perkins Caufield & Byers Xv...,
  
• David V Goeddel,
  Director
• Group Ii, Lp Column Group I...,
  
• Group Ii, Lp Column Group I...,
  
• Group Ii, Lp Column Group I...,
  
• Fund L.P.Topspin Biotech Fu...,
  
• Karen C Lam,
  VP, Finance and Controller
• Lori Lyons Williams,